Therapeutic effects of Curcumin capsule in patients with amyotrophic lateral sclerosis

Therapeutic effects of Curcumin in patients with amyotrophic lateral sclerosis reffered to neurologic research center of imam khomeini hospital

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015062411424N3

Enrollment

Registered

2016-07-01

Start date

2015-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic lateral sclerosis(AlS). Motor neuron disease

Interventions

Intervention 1: Control: In this group, patients will recieve capsule placebo daily besides tablet Riluzole 50mg BD. Intervention 2: Intervention: In this group, patients will recieve capsule Sina Cur

Placebo

Treatment - Drugs

Control: In this group, patients will recieve capsule placebo daily besides tablet Riluzole 50mg BD

Intervention: In this group, patients will recieve capsule Sina Curcumin 80 mg daily and tablet Riluzole 50mg BD

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with an age range of 18 to 85; Probable or definite ALS (based on revised El Escorial criteria); Time passed since onset of the symptoms till inclusion be 2 years or less; Mild to moderate disability (based on ALSFRS-r) Exclusion criteria: Familial ALS in first-degree relatives; Pregnancy or breastfeeding; Severe renal, liver or heart dysfunction; HIV positive patients; Prominant cognitive impairment

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Patients clinical function changes. Timepoint: baseline,3 months after intervention. Method of measurement: ALS Functional Rating Scale.	—

Secondary

Measure	Time frame
Compound muscle action potential (CMAP) changes in ulnar nerve. Timepoint: baseline, 3 months after intervention. Method of measurement: EMG-NCV.;Muscle strength changes. Timepoint: baseline, 3 months after intervention. Method of measurement: Manual muscle testing.;Compound muscle action potential (CMAP) changes in proneal nerve. Timepoint: baseline, 3 months after intervention. Method of measurement: EMG-NCV.;Quality of life. Timepoint: baseline, 3 months after intervention. Method of measurement: ALSAQ-40.;Medication side effects. Timepoint: 3 months after intervention. Method of measurement: questionnaire.	—

Measure

Time frame

Compound muscle action potential (CMAP) changes in ulnar nerve. Timepoint: baseline, 3 months after intervention. Method of measurement: EMG-NCV.;Muscle strength changes. Timepoint: baseline, 3 months after intervention. Method of measurement: Manual muscle testing.;Compound muscle action potential (CMAP) changes in proneal nerve. Timepoint: baseline, 3 months after intervention. Method of measurement: EMG-NCV.;Quality of life. Timepoint: baseline, 3 months after intervention. Method of measurement: ALSAQ-40.;Medication side effects. Timepoint: 3 months after intervention. Method of measurement: questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbbas Tafakhori

Tehran University of Medical Sciences

abbas.tafakhori@gmail.com+98 21 6119 2424

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026